About Actin-related protein 2/3 complex subunit 1A
Actin-related protein 2/3 complex subunit 1A (ARPC1A) is a protein
from Homo sapiens identified by UniProt accession
Q92747, 370 residues long.
MolForge cross-references it against 0 known binders and
50 disease associations.
Target properties
| Protein name | Actin-related protein 2/3 complex subunit 1A |
| UniProt accession | Q92747 |
| Gene | ARPC1A |
| Organism | Homo sapiens |
| Length | 370 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (50)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.53
- cutaneous Leishmaniasis · score 0.37
- pancreatic adenocarcinoma · score 0.21
- lymphocyte count · score 0.19
- alcohol consumption measurement · score 0.19
- endometrial cancer · score 0.18
- breast adenocarcinoma · score 0.18
- hormone measurement · score 0.17
- serum metabolite measurement · score 0.15
- alcohol use disorder measurement · score 0.14
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q92747-F1 | alphafold | PREDICTED | 92.23 | — |
Amino-acid sequence (370 residues)
MSLHQFLLEP ITCHAWNRDR TQIALSPNNH EVHIYKKNGS QWVKAHELKE HNGHITGIDW APKSDRIVTC GADRNAYVWS QKDGVWKPTL VILRINRAAT FVKWSPLENK FAVGSGARLI SVCYFESEND WWVSKHIKKP IRSTVLSLDW HPNNVLLAAG SCDFKCRVFS AYIKEVDEKP ASTPWGSKMP FGQLMSEFGG SGTGGWVHGV SFSASGSRLA WVSHDSTVSV ADASKSVQVS TLKTEFLPLL SVSFVSENSV VAAGHDCCPM LFNYDDRGCL TFVSKLDIPK QSIQRNMSAM ERFRNMDKRA TTEDRNTALE TLHQNSITQV SIYEVDKQDC RKFCTTGIDG AMTIWDFKTL ESSIQGLRIM
Explore Actin-related protein 2/3 complex subunit 1A with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets